Ae­glea Bio­Ther­a­peu­tics ac­quires start­up Spyre in bid to go af­ter Mer­ck’s Prometheus, Roivant’s Tela­vant

Af­ter putting up the strate­gic al­ter­na­tive signs in April, rare dis­ease drug de­vel­op­er Ae­glea Bio­Ther­a­peu­tics is now look­ing to go in a new di­rec­tion with the ac­qui­si­tion of Spyre Ther­a­peu­tics.

The com­bined com­pa­ny will have $220 mil­lion in cash and equiv­a­lents at close to fund it­self in­to 2026. The biotech will go af­ter big am­bi­tions in au­toim­mune dis­eases, tar­get­ing the same mech­a­nism of ac­tion as Take­da’s En­tyvio and the block­buster-hyped TL1A drugs out of Mer­ck’s Prometheus and Roivant’s Tela­vant, which came out with more ul­cer­a­tive col­i­tis da­ta this morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER